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Bisphosphonates (BPs) are the most common treatment for osteoporosis, due 
to their powerful ability to inhibit osteoclastic bone resorption. They are also being 
investigated to augment callus production during fracture healing, however, concerns 
exist as to the effects of BPs during both initial fracture union and hard callus 
remodelling. Endochondral ossification during fracture repair is a critical process 
leading to initial union, and is assumed to be dependent on osteoclast function. Hard 
callus remodelling, known to be dependent on osteoclast function, is important to the 
completion of bone repair.  
The role of osteoclasts during initial endochondral fracture union was 
investigated using the BP zoledronic acid (ZA) and in a genetic model of osteoclast 
inactivity, the incisor absent (ia/ia) rat. In addition, the effect of differing ZA treatment 
regimes on hard callus remodelling was investigated using both Bolus and Weekly ZA 
dosing. A Bolus of 0.1mg/kg ZA or 5 Weekly doses of 0.02mg/kg ZA or Saline were 
administered commencing 1 week post surgery in a rat femoral fracture model. 
Femoral fractures were also produced in ia/ia rats. Examinations were performed up to 
initial union and throughout callus remodelling. 
ZA treatment did not alter the rate of endochondral fracture union. All fractures 
united by 6 weeks, with no difference in the percentage of cartilaginous callus between 
treatment groups at any time point. Fracture union was achieved by 3 weeks in both 
ia/ia and control rats, again with no difference in the percentage of cartilaginous callus. 
In contrast, marked differences in hard callus were evident in the ZA treated 
groups. ZA increased callus bone mineral content, volume and importantly increased 
callus strength. Bolus ZA treatment did not delay the commencement of hard callus 
remodelling at 4 weeks post fracture, whereas this was delayed in the Weekly ZA 
group. By 12 and 26 weeks Bolus ZA had the same callus content of remodelled neo-
cortical bone as Saline, however Weekly ZA had significantly less than saline at these 
times. These extensive delays in hard callus remodelling with Weekly ZA dosing 
produced a fracture callus of inferior material properties. 
In conclusion, neither ZA treatment nor the absence of active osteoclasts in  
ia/ia rats delayed endochondral fracture union. Thus, this study confirms the 
redundancy of osteoclasts in this process. Bolus ZA treatment was superior to Weekly 
ZA dosing; hard callus remodelling proceeded, producing a strong fracture callus with 
improved material properties. This study supports the use of less frequent ZA doses 
during fracture repair.
